TSC Talks 3.0~What Did We Sign? Data, Consent, and the Gene Therapy Machine
SHOW NOTES - Dear TSC Alliance Leadership and Natural History Database Steering Committee,.pdf- TSC Alliance contact: [email protected] Host contact: Jill Woodworth ([email protected])- MA AG consumer complaint form: mass.gov/how-to/file-a-consumer-complaint- Apertura Gene Therapy press release (May 2026)- TSC Alliance NHD page: tscalliance.org- Van Andel Institute Biorepository: Grand Rapids, MI- Key terms: AAV, TSC1, TSC2, vector sizing, DRG toxicity, antibody neutralization, 15-year FDA follow-up mandate---KEY DEFINITIONS*AAV Capsid Delivery Platform: An adeno-associated virus (AAV) vector system engineered to deliver functional genetic material into host cells. In this context, it utilizes a viral shell (capsid) to cross specific biological barriers and target neural tissues. Key operational constraints and clinical considerations include:*Packaging Limits: AAV vectors have a strict genetic payload capacity of approximately 4.7 kilobases total (including ITRs), leaving roughly 4.4 kilobases for the transgene cassette. Genes exceeding this length (such as full-length TSC2, at ~4.3 kb coding sequence plus necessary promoter and polyA signals) present significant packaging challenges.*Immune Response & Irreversibility:** Exposure to an AAV capsid triggers neutralizing antibody production by the patient's immune system, permanently barring subsequent administration of AAV-based treatments.*Monitoring Requirements: Regulatory standards (such as FDA mandates) require extended long-term follow-up monitoring—typically lasting up to 15 years—to evaluate long-term safety, potential hepatotoxicity, and dorsal root ganglion (DRG) toxicity.I discuss the TSC gene therapy agreement and the TSC Natural History Database (NHD), raising questions about consent, data governance, and long-term impacts on families. I explains the NHD’s scope (running since 2006 with 2,700+ participants, clinical histories and biosamples stored at Van Andel Institute, and thousands of samples distributed to researchers) and critiques the May 2026 TSC Alliance partnership with for-profit Apertura Gene Therapy, backed by Deerfield Management, to develop an AAV gene replacement therapy delivering TSC1/TSC2 to the brain. I outline concerns about lack of reconsent when minors become adults, unclear withdrawal processes, financial protections for participants, and under-communicated risks of AAV therapies (high cost, permanent antibody barrier to future AAV dosing, 15-year monitoring, and TSC2 packaging constraints). I describe a certified letter demanding written answers and offers steps for parents to request consent forms, ask about withdrawal, and file complaints if needed.00:00 Intro and Big Questions01:57 What We Signed02:34 Inside the NHD Database03:47 Apertura Partnership Explained04:59 Consent and Governance Gaps06:30 Gene Therapy Risks Breakdown09:29 My Certified Letter09:37 Five Demands for Transparency12:35 What You Can Do Now14:48 Final Thoughts and Wrap Up https://aperturagtx.com/news/apertura-gene-therapy-and-the-tsc-alliance-announce-collaboration-to-advance-gene-therapy-programs-designed-to-treat-tuberous-sclerosis-complex-tsc/https://www.prnewswire.com/news-releases/apertura-gene-therapy-showcases-the-progress-of-its-novel-human-transferrin-receptor-aav-capsid-tfr1-capx-and-preclinical-programs-for-tuberous-sclerosis-complex-tsc-at-the-american-society-of-gene-and-cell-therapy-asgct-ann-302448607.html https://www.prnewswire.com/news-releases/tsc-alliance-and-apertura-gene-therapy-complete-preclinical-pilot-study-evaluating-aav-gene-therapy-approach-designed-for-tsc1-302838523.htmlBecome a supporter of this podcast: https://www.spreaker.com/podcast/tsc-talks--1666046/support.